The Immunomodulatory Effect of Sugammadex After Total Hip Replacement Surgery Under Neuraxial Anaesthesia: a Pilot Study

Inclusion Criteria: * Age of 18 years or older * Scheduled for total hip replacement surgery under neuraxial anesthesia * Scheduled for primary hip replacement surgery * Informed consent obtained Exclusion Criteria: * Insufficient control of the Dutch language to read the patient information and to fill out the questionnaires * Mentally incapacitated patients * Known or suspected hypersensitivity to sugammadex * Deficiency of vitamin K dependent clotting factors or coagulopathy * Severe renal disease (creatinine clearance \<30 ml/min), including patients on dialysis) * Severe liver disease (Child-Pugh Classification C) * Women who are or may be pregnant or currently breastfeeding * Women of childbearing potential who don't use adequate method of contraception * Severe vertebral column disorder * Chronic use of psychotropic drugs * Known hypertrophic obstructive cardiomyopathy, severe aortic valve stenosis or severe mitral valve stenosis * Chronic use of NSAID's, steroids or immunosuppressive drugs